QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://twitter.com/DrTedros/status/1778423967105139108  

 geovax-to-present-data-on-geo-cm04s1-a-next-generation-covid-19-vaccine-at-the-world-vaccine-congress

GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...

 geovax-labs-inc-files-for-mixed-shelf-of-up-to-100m

– SEC Filing

 geovax-labs-q4-earnings-insights
Geovax Labs: Q4 Earnings Insights
02/29/2024 21:10:39

 geovax-labs-q4-2023-gaap-eps-3940-misses-2780-estimate

Geovax Labs (NASDAQ:GOVX) reported quarterly losses of $(3.940) per share which missed the analyst consensus estimate of $(2.78...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

 earnings-outlook-for-geovax-labs
Earnings Outlook For Geovax Labs
02/28/2024 19:02:14

 inmed-pharmaceuticals-and-2-other-penny-stocks-insiders-are-buying

The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their con...

 geovax-announces-multiple-actions-by-global-patent-offices-strengthening-the-companys-intellectual-property-assets-intellectual-property-assets-strengthened-for-cancer-immunotherapy-program-and-for-marburg-virus-and-hiv-vaccines

Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV VaccinesATLANTA, GA, Fe...

 geovax-reports-interim-data-from-phase-2-clinical-trial-of-geo-cm04s1-as-universal-covid-19-vaccine-booster

Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants

 geovax-announces-issuance-of-malaria-vaccine-patent-patent-covers-multiple-component-vaccine-for-both-prevention-and-treatment

Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via N...

Core News & Articles

The Dow Jones index closed higher by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their conf...

 geovax-expands-rights-under-nih-covid-19-license-to-include-mpox-and-smallpox-financial-terms-of-the-license-agreement-were-not-disclosed

GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION